New Stock News | Simec Pharmaceutical Second Filing to Hong Kong Stock Exchange
According to the disclosure by the Hong Kong Stock Exchange on May 18th, Zhejiang Shimai Pharmaceutical Co., Ltd. (hereinafter referred to as Shimai Pharmaceutical) has submitted a second listing application to the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor.
According to the disclosure from the Hong Kong Stock Exchange on May 18th, Zhejiang Shimai Pharmaceutical Co., Ltd. (hereinafter referred to as Shimai Pharmaceutical) has submitted a second listing application to the Hong Kong Stock Exchange Main Board, with Huatai International as its exclusive sponsor. According to the prospectus, Shimai Pharmaceutical is a clinical-stage biotechnology company focused on the development of T-cell engage therapies. The company has four pipeline products in clinical development, including two core products (DNV3 for the treatment of advanced/metastatic solid tumors and lymphomas, and SMET12 for the treatment of EGFR-positive advanced solid tumors).
Related Articles
Shenzhen Leading Semiconductor Industry (603991.SH) intends to change its securities abbreviation to "Leading Shares".
NIngbo Boway Alloy Material (601137.SH) subsidiary plans to transfer rights to tax exemptions for the production of advanced manufacturing industry in the United States.
TONGCHENGTRAVEL Zhihu releases 2026 Museum Travel Trend Report: 1 out of every 8 sightseeing reservation users visits a museum.
Shenzhen Leading Semiconductor Industry (603991.SH) intends to change its securities abbreviation to "Leading Shares".
NIngbo Boway Alloy Material (601137.SH) subsidiary plans to transfer rights to tax exemptions for the production of advanced manufacturing industry in the United States.
TONGCHENGTRAVEL Zhihu releases 2026 Museum Travel Trend Report: 1 out of every 8 sightseeing reservation users visits a museum.
